Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
- PMID: 15262104
- DOI: 10.1016/S0140-6736(04)16676-2
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
Abstract
Background: Present treatment strategies for rheumatoid arthritis include use of disease-modifying antirheumatic drugs, but a minority of patients achieve a good response. We aimed to test the hypothesis that an improved outcome can be achieved by employing a strategy of intensive outpatient management of patients with rheumatoid arthritis--for sustained, tight control of disease activity--compared with routine outpatient care.
Methods: We designed a single-blind, randomised controlled trial in two teaching hospitals. We screened 183 patients for inclusion. 111 were randomly allocated either intensive management or routine care. Primary outcome measures were mean fall in disease activity score and proportion of patients with a good response (defined as a disease activity score <2.4 and a fall in this score from baseline by >1.2). Analysis was by intention-to-treat.
Findings: One patient withdrew after randomisation and seven dropped out during the study. Mean fall in disease activity score was greater in the intensive group than in the routine group (-3.5 vs -1.9, difference 1.6 [95% CI 1.1-2.1], p<0.0001). Compared with routine care, patients treated intensively were more likely to have a good response (definition, 45/55 [82%] vs 24/55 [44%], odds ratio 5.8 [95% CI 2.4-13.9], p<0.0001) or be in remission (disease activity score <1.6; 36/55 [65%] vs 9/55 [16%], 9.7 [3.9-23.9], p<0.0001). Three patients assigned routine care and one allocated intensive management died during the study; none was judged attributable to treatment.
Interpretation: A strategy of intensive outpatient management of rheumatoid arthritis substantially improves disease activity, radiographic disease progression, physical function, and quality of life at no additional cost.
Comment in
-
Intensive management reduced disease activity in rheumatoid arthritis.ACP J Club. 2004 Nov-Dec;141(3):70. ACP J Club. 2004. PMID: 15518454 No abstract available.
Similar articles
-
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.Lancet. 2004 Feb 28;363(9410):675-81. doi: 10.1016/S0140-6736(04)15640-7. Lancet. 2004. PMID: 15001324 Clinical Trial.
-
Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis.J Rheumatol. 2007 Feb;34(2):316-21. Epub 2006 Dec 15. J Rheumatol. 2007. PMID: 17183623 Clinical Trial.
-
Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.Arthritis Rheum. 2008 May;58(5):1310-7. doi: 10.1002/art.23449. Arthritis Rheum. 2008. PMID: 18438851 Clinical Trial.
-
Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target.Bull Hosp Jt Dis (2013). 2013;71 Suppl 1:S33-40. Bull Hosp Jt Dis (2013). 2013. PMID: 24219039 Review.
-
Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity.Arthritis Res Ther. 2006;8(4):216. doi: 10.1186/ar1983. Arthritis Res Ther. 2006. PMID: 16879719 Free PMC article. Review.
Cited by
-
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.Nat Rev Rheumatol. 2015 May;11(5):276-89. doi: 10.1038/nrrheum.2015.8. Epub 2015 Feb 17. Nat Rev Rheumatol. 2015. PMID: 25687177 Review.
-
Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort.BMJ Open. 2013 Jul 31;3(7):e003083. doi: 10.1136/bmjopen-2013-003083. BMJ Open. 2013. PMID: 23903812 Free PMC article.
-
Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.Clin Rheumatol. 2016 Jul;35(7):1673-81. doi: 10.1007/s10067-016-3306-x. Epub 2016 May 17. Clin Rheumatol. 2016. PMID: 27188857
-
Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review.Adv Ther. 2020 Sep;37(9):3732-3745. doi: 10.1007/s12325-020-01437-4. Epub 2020 Aug 1. Adv Ther. 2020. PMID: 32740789 Free PMC article. Review.
-
Disease Activity Indices in Rheumatoid Arthritis: Comparative Performance to Detect Changes in Function, IL-6 Levels, and Radiographic Progression.Front Med (Lausanne). 2021 May 31;8:669688. doi: 10.3389/fmed.2021.669688. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34136506 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical